Literatur
-
1
Agewall S, Fagerberg B.
Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men.
Clin Cardiol.
2002;
25
287-290
-
2
Akaike M, Azuma H, Kagawa A. et al .
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
Clin Chem.
2002;
48
1454-1459
-
3
Angelin B.
Therapy of lowering lipoprotein(a) levels.
Curr Opin Lipidol.
1997;
8
337-341
-
4
Armstrong V W, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D.
Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels.
Eur J Clin Invest.
1989;
19
235-240
-
5
Bambauer R, Schiel R, Latza R.
Low-density Lipoprotein Apheresis: An Overview.
Therap Apher Dial.
2003;
7
382-390
-
6
Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M.
Lipoprotein(a) in the arterial wall.
Eur Heart J.
1990;
11
174-183
(Suppl E)
-
7
Berg K.
A new serum type system in man: the LP system.
Acta Pathol Microbio Scand.
1963;
59
369-382
-
8
Boerwinkle E.
Genetics of plasma lipoprotein(a) concentrations.
Curr Opin Lipidol.
1992;
3
128-136
-
9
Bosch T, Keller C.
Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction.
Therap Apher Dial.
2003;
7
341-344
-
10
Cantin V, Gagnon F, Moorjani S. et al .
Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study.
J Am Coll Cardiol.
1998;
31
519-525
-
11
Carlson L A, Hamsten A, Asplund A.
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.
J Intern Med.
1989;
226
271-176
-
12
Cremer P, Nagel D, Mann H. et al .
Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men.
Atherosclerosis.
1997;
129
221-230
-
13
Crouse J R.
New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
Coron Artery Dis.
1996;
7
321-326
-
14
Dahlen G H, Guyton J R, Attar M, Farmer J A, Kautz J A, Gotto A M.
Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography.
Circulation.
1986;
74
758-765
-
15
Danesh J, Collins R, Peto R.
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.
Circulation.
2000;
102
1082-1085
-
16
Dangas G, Mehran R, Harpel P C. et al .
Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation.
J Am Coll Cardiol.
1998;
32
2035-2042
-
17
Dujovne C A, Harris W S, Altman R, Overhiser R W, Black D M.
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
Am J Cardiol.
2000;
85
350-353
-
18
Espeland M A, Marcovina S M, Miller V. et al. for the PEPI investigators .
Effect of postmenopausal hormone therapy on lipoprotein(a) concentration.
Circulation.
1998;
97
979-986
-
19
Evans R W, Shpilber O, Shaten B J, Ali S, Kamboh I, Kuller L.
Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial.
J Clin Epidemiol.
2001;
54
51-57
-
20
Executive summary of the third report of the national cholesterol education programm (NECP) .
Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III).
JAMA.
2001;
285
2486-2497
-
21
Frank S, Gauster M, Strauss J, Hrzenjak A, Kostner G M.
Adenovirus mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo.
Gene Therapy.
2001;
8
425-430
-
22
Ginsberg H N, Kris-Etherton P, Dennis B. et al .
Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1.
Arterioscler Thromb Vasc Biol.
1998;
18
441-449
-
23
Gonbert S, Malinsky S, Sposito A C. et al .
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.
Atherosclerosis.
2002;
164
305-311
-
24
Grainger D J, Kirschenlohr H L, Mecalfe J C, Weissberg P L, Wade D P, Lawn R M.
Proliferation of human smooth muscle cells promoted by lipoprotein(a).
Science.
1993;
260
1655-1658
-
25
Harpel P C, Chang V T, Borth V.
Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism.
Proc Natl Acad Sci USA.
1992;
89
10& hairsp;193-10 197
-
26
Hervio L, Chapman J M, Thillet J, Loyau S, Anglés-Cano E.
Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?.
Blood.
1993;
82
392-397
-
27
Jauhiainen M, Koskinen P, Ehnholm. et al .
Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.
Atherosclerosis.
1991;
89
59-67
-
28
Jenkins D J, Kendall C W, Marchie A. et al .
Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial.
Circulation.
2002;
106
1327-1332
-
29
Kiortsis D N, Tzotas T, Giral P. et al .
Changes in lipoprotein(a) levels and hormonal correlation during weight reduction program.
Nutr Metab Cardiovasc Dis.
2001;
11
153-157
-
30
Koschinsky M L, Marcovina S M.
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.
Curr Opin Lipidol.
2004;
15
167-174
-
31
Kronenberg F, Kronenberg M F, Kiechl S. et al .
Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study (editorial).
Circulation.
1999;
100
1154-1160
-
32
Kronenberg F, Neyer U, Lhotta K. et al .
The low molecular weight apo(a)-phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow up.
J Am Soc Nephrol.
1999;
10
1027-1036
-
33
Loscalzo J, Weinhold M, Fless G M, Scanu A M.
Lipoprotein(a), fibrin binding and plasminogen activation.
Arteriosclerosis.
1990;
10
240-245
-
34
Luc G, Bard J M, Arveiler D. et al on behalf of the PRIME study group .
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.
Atherosclerosis.
2002;
163
377-384
-
35
Marcovina S M, Koschinsky M L.
Lipoprotein(a) concentration and apolipoprotein(a) size - a synergistic role in advanced atherosclerosis?.
Circulation.
1999;
100
1151-1153
-
36
Marcovina S M, Koschinsky M L, Albers J J, Skarlatos S.
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions.
Clin Chem.
2003;
49
1785-1796
-
37
McLean J W, Tomlinson J E, Kuang W J. et al .
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.
Nature.
1987;
300
132-137
-
38
Miles L A, Fless G M, Levin E G, Scanu A M, Plow E F.
A potential basis for the thrombotic risks associated with lipoprotein(a).
Nature.
1989;
339
301-303
-
39
Miwa K, Nakagawa K, Yoshida N, Taguchi Y, Inoue H.
Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm.
J Amer Coll Cardiol.
2000;
35
1200-1205
-
40
Nomura S, Yamamura T, Yamamoto A. et al .
The association between lipoprotein(a) and severity of coronary and cerebrovascular atherosclerosis, especially in non-hypercholesterolemic subjects.
Cardiovasc Risk Fact.
1993;
3
336-343
-
41
Nowak-Göttl U, Junker F, Hartmeier M. et al .
Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood.
Circulation.
1999;
100
743-748
-
42 Phillips B, Ball C, Sackett D. et al .Levels of evidence and grades of recommendation. Oxford: Oxford-Centre for Evidence Based Medicine 2001
-
43
Plenge J K, Hernandez T L, Weil K M. et al .
Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction.
Circulation.
2002;
106
1447-1452
-
44
Pokrovsky S N, Sussekov A, Afanasieva O I, Adamova I Y, Lyakishev A A, Kukharchuk V V.
Extracorporal immunadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data.
Chem Phys Lipids.
1994;
67/68
323-330
-
45
Scanu A M.
Lipoprotein(a) and the atherothrombotic process: Mechanistics insights and clinical implications.
Curr Atheroscler Rep.
2003;
5
106-113
-
46
Schuff-Werner P, Gohlke H, Bartmann U. et al. and the HELP study group .
The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease.
Eur J Clin Invest.
1994;
24
724-732
-
47
Seed M, Hoppichler F, Reaveley D. et al .
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.
N Engl J Med.
1990;
322
1494-1499
-
48
Shewmon D A, Stock J L, Rosen C J. et al .
Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.
Arterioscler Thromb.
1994;
14
1586-1593
-
49
Sirtori C R, Calabresi L, Ferrara S. et al .
L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a).
Nutr Metab Cardiovasc Dis.
2000;
10
247-251
-
50
Terres W, Tatsis E, Pfalzer B, Beil F U, Beilsiegel U, Hamm C W.
Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a).
Circulation.
1995;
91
948-950
-
51
Thompson G R, Maher V M, Matthews S, Kitano Y, Neuwirth C, Shortt M B.
Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis.
Lancet.
1995;
345
811-816
-
52
Ullrich H, Lackner K J, Schmitz G.
Lipoprotein(a) apheresis in severe coronary heart disease: an immunadsorption method.
Artif Org.
1998;
22
135-139
-
53
Von Depka M, Nowak-Göttl U, Eisert R. et al .
Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism.
Blood.
2000;
96
3364-3368
-
54
Von Eckardstein A, Schulte H, Cullen P, Assmann G.
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk.
J Am Coll Cardiol.
2001;
37
434-439
Dr. med. Roman Leischik
Mittelstraße 13
58095 Hagen
Phone: 02331/182500
Fax: 02331/182570
Email: literatur@dr-leischik.de
